Tag: licence

Novartis&#39 Glivec extends European GIST licence Novartis&#39 cancer therapy Glivec (imatinib) can now be used in Europe to treat specific patients with gastrointestinal stromal tumours (GIST) up to 3 years right after surgery. The European Commission (EC) has approved an update to the labelling for the … Read much more on PMLiVE Positive Vote for…